Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-017-16658-x
Title: Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients
Authors: Li, F.-F
Liu, B.-L
Yin, G.-P
Zhang, D.-F
Zhai, X.-F
Chen, M.-Y
Su, X.-F
Wu, J.-D
Ye, L 
Ma, J.-H
Keywords: antidiabetic agent
biological marker
insulin
metformin
adult
blood
combination drug therapy
female
glucose blood level
human
male
middle aged
non insulin dependent diabetes mellitus
onset age
randomized controlled trial (topic)
treatment outcome
Adult
Age of Onset
Biomarkers
Blood Glucose
Diabetes Mellitus, Type 2
Drug Therapy, Combination
Female
Humans
Hypoglycemic Agents
Insulin
Male
Metformin
Middle Aged
Randomized Controlled Trials as Topic
Treatment Outcome
Issue Date: 2017
Citation: Li, F.-F, Liu, B.-L, Yin, G.-P, Zhang, D.-F, Zhai, X.-F, Chen, M.-Y, Su, X.-F, Wu, J.-D, Ye, L, Ma, J.-H (2017). Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients. Scientific Reports 7 (1) : 16382. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-017-16658-x
Rights: Attribution 4.0 International
Abstract: It is unknown whether YOD (young onset diabetes) and LOD (late onset diabetes) require similar insulin doses for intensive insulin therapy with a metformin add-on to achieve glycemic control. We analyzed data from our two previously performed randomized, controlled open-label trials. Patients were randomized to receive either continuous subcutaneous insulin infusion (CSII) therapy or CSII combined with metformin therapy for 4 weeks. The studies concentrated on the differences in the insulin doses used for the two groups. We included 36 YOD (age < 40 yrs) and 152 LOD (age > 40 yrs) patients. YOD patients who received metformin combined with CSII therapy required significantly lower insulin doses to maintain euglycemic control compared to patients with LOD. A multivariate analysis, controlled for gender and the fasting blood concentration, was performed to determine the significance of the differences between groups, particularly with respect to the total and basal insulin doses. There was a trend toward improvement in ?-cell function and insulin resistance in terms of ?HOMA-B and ?HOMA-IR in patients with YOD compared to those with LOD. Newly diagnosed T2D patients with YOD required significantly lower insulin doses, particularly basal insulin doses, to maintain glycemic control compared to the LOD patients. © 2017 The Author(s).
Source Title: Scientific Reports
URI: https://scholarbank.nus.edu.sg/handle/10635/178297
ISSN: 20452322
DOI: 10.1038/s41598-017-16658-x
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-017-16658-x.pdf1.09 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

6
checked on Nov 20, 2020

Page view(s)

6
checked on Nov 19, 2020

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons